午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频
Shanghaizehan biopharma technology co., Ltd.??? ?? ??? ?????.
?? ?:
Shanghaizehan biopharma technology co., Ltd.
??:
021-61350663
???:
sales@zehanbiopharma.com
??:
China
URL:
http://www.zehanbiopharma.com
? ?? ?:
986
3
4
5
6
7
8
9
10
?? ????
Dynasore
304448-55-3
C18H14N2O4
AK120765
955272-06-7
C19H15ClN4O2
AST487
630124-46-8
C26H30F3N7O2
Volitinib
????
1313725-88-0
C17H15N9
M-2951 (Evobrutinib)
1415823-73-2
C25H27N5O2
DMU2105
1031063-36-1
C18H13NO
MAC-545496
838810-96-1
C18H18ClN5O3S
Datelliptium chloride
????
105118-14-7
Abexinostat (PCI-24781)
783355-60-2
C21H23N3O5
R1487
449808-64-4
C19H19ClF2N4O3
BMS-687453
1000998-59-3
C22H21ClN2O6
cGAMP
849214-04-6
C20H24N10O13P2
VLX600
1622945-04-3
C17H17N7
AM-0902
1883711-97-4
C17H15ClN6O2
PLX5622
1303420-67-8
C21H19F2N5O
CK869
388592-44-7
C17H16BrNO3S
PEO-IAA
6266-66-6
C18H15NO3
SAR-20347
1450881-55-6
C21H18ClFN4O4
E-7046
1369489-71-3
C22H18F5N3O4
SB366791
4'-???-3-??????????
472981-92-3
C16H14ClNO2
AMG-510
2252403-56-6
C30H30F2N6O3
TH 5487
2304947-71-3
C19H18BrIN4O2
SU-5607
186611-52-9
C18H17NO4
KN-93 base or HCI
139298-40-1
C26H29ClN2O4S
Fumagillol
108102-51-8
C16H26O4
mTOR inhibitor-1
468747-17-3
C16H15BrN2O3
XMD 8-92
1234480-50-2
C26H30N6O3
SRT2104 (GSK2245840)
1093403-33-8
C26H24N6O2S2
SGC0946
1561178-17-3
C28H40BrN7O4
PD0166285
185039-89-8
C26H27Cl2N5O2
LEE011 (Ribociclib)
1211441-98-3
C23H30N8O
G007-LK
1380672-07-0
C25H16ClN7O3S
WH-4-023
837422-57-8
C32H36N6O4
BI671800
1093108-50-9
C25H26F3N5O3
JNJ26854165 2HCl
JNJ26854165(??????)2HCl
875320-31-3
C21H27ClN6O2
LY2606368 dihydrochloride
1234015-54-3
C18H21Cl2N7O2
IDE196
1874276-76-2
C22H23F3N8O
DMU2139
104890-70-2
C19H15NO2
TRi-1
246020-68-6
C12H9ClN2O5S
Pixantrone maleate
??(g)?????-5,10-??,6,9-??((2-?????)???)-,(2Z)-2-???????(1:2)
144675-97-8
C21H23N5O6
Aurora kinase inhibitor III
?????????III
879127-16-9
C21H18F3N5O
SGI 1027
1020149-73-8
C27H23N7O
CPI-444
1202402-40-1
C20H21N7O3
AF64394
1637300-25-4
C21H20ClN5O
BO-264
2408648-20-2
C18H19N5O3
KN92 phosphate
KN92???
1135280-28-2
C24H28ClN2O7PS
APY29
1216665-49-4
C17H16N8
GSK2982772
1622848-92-3
C20H19N5O3
Seclidemstat
1423715-37-0
C20H23ClN4O4S
GLX351322
835598-94-2
C21H25N3O5S
ZT-12-037-01
2328073-61-4
C21H31N5O2
ML792
1644342-14-2
C21H23BrN6O5S
NTP-42
2055599-51-2
C25H23F2N3O5S
NS-3-008
1172854-54-4
C14H24ClN3
GlyH-101
328541-79-3
C19H15Br2N3O3
SD-06-1
271576-80-8
C20H20ClN5O2
ALK inhibitor 2
ALK???2
761438-38-4
C23H28ClN7O3S
FG2216
223387-75-5
C12H9ClN2O4
GKT137831
1218942-37-0
C21H19ClN4O2
URMC-099
1229582-33-5
C27H27N5
TD-4208
864750-70-9
C35H43N5O4
XMU-MP-1
2061980-01-4
C17H16N6O3S2
SSE15206
1370046-40-4
C19H21N3O3S
ZM223
2031177-48-5
C23H17F3N4O2S2
NDI-091143
2375840-87-0
C20H14ClF2NO5S
FEN1 Inhibitor C2
1995893-58-7
C12H12N2O3
GW2580
870483-87-7
C20H22N4O3
GDC-0623
1168091-68-6
C16H14FIN4O3
ON123300
1357470-29-1
C24H27N7O
SGC2085
1821908-48-8
C19H24N2O2
XMD-17-51
1628614-50-5
C21H24N8O
TRPM8 antagonist 2
259674-19-6
C26H26N2O2
ML-109
1186649-91-1
C31H29N3O5
PD173955
260415-63-2
C21H16Cl2N4OS
ID 8 free base
147591-46-6
C16H14N2O4
SGI-1776
1025065-69-3
C20H22F3N5O
LY2886721 HCl
1262036-49-6
C18H16F2N4O2S.HCl
KD025 (SLx-2119)
ROCK???2
911417-87-3
C26H24N6O2
AS1517499
919486-40-1
C20H20ClN5O2
4SC-202 tosylate
1186222-89-8
C30H29N5O6S2
Glasdegib
1095173-27-5
C21H22N6O
FRAX486
1232030-35-1
C25H23Cl2FN6O
Tomivosertib eFT508
1849590-01-7
C17H20N6O2
SNS-062
1270014-40-8
C19H21ClN6O
Autophinib
1644443-47-9
C14H11ClN6O3
ACH-4471
1903768-17-1
C26H23BrFN7O3
AZD 7648
2230820-11-6
C18H20N8O2
Emedastine
87233-61-2
C17H26N4O
PD-166285
212391-63-4
C26H29Cl4N5O2
Fatostatin A
125256-00-0
C18H18N2S
Hydroxy-Dynasore
2-?????????,3-????-,2-[(2,4,5-????????)???]?????
1256493-34-1
C18H14N2O5
Entospletinib (GS-9973)
1229208-44-9
C23H21N7O
MHY1485
326914-06-1
C17H21N7O4
BBT594
???594
882405-89-2
C28H30F3N7O3
MD2-IN-1
111797-22-9
C20H22O6
(+/-)-BAY K 8644
71145-03-4
C16H15F3N2O4
LY-3381916
2166616-75-5
C23H25FN2O3
FEN1 Inhibitor C3
2109805-87-8
C15H12N2O4
TYRPHOSTIN AG 528
133550-49-9
C18H14N2O3
3
4
5
6
7
8
9
10
Copyright 2019 ? ChemicalBook. All rights reserved